Highlights
About
Design and Construction of Viral-based Products
SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology. The company utilizes a multidisciplinary approach combining technologies, such as synthetic biology, virology, bio-informatics, engineering, and robotics, to make viruses that can be used to develop new vaccines. SynVaccine's technology enables the design and fabrication of viral genomes using a safety-focused design approach. The resulting viruses have the potential to overcome the limitations of those found in nature or developed through traditional technologies. SynVaccine was founded as part of Rad BioMed, an Israel-based evergreen family fund that invests in early-stage biomedical start-ups, and on the basis of commercialized research from Tel Aviv University and Weizmann Institute of Science led by Professor Tamir Tuller.
Identity
| Name | SynVaccine |
|---|---|
| Slug | synvaccine |
| Type / kind | startup |
| Crunchbase ID | syn-vaccine |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6_pJ4LDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | HaBarzel Street 27, Tel Aviv-Yafo, Israel |
Web & social
| Website | https://www.synvaccine.com |
|---|
Classifications
Funding
| Total raised | $1.8M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}